Figure legends
Figure 1 . Comprehensive summary data on COVID-19
clinical trials completed, in progress, or in advanced planning stages
as of April 17, 2020. Trial data were organized according to drug and
target or pharmacologic mechanism, along with results and pertinent
literature from any preliminary COVID-19 studies (or prior SARS and MERS
studies), trial ID and phase, and data on investigational scale and
structure including number of participants, blinding, single vs.
multi-center status, and estimated completion date.
Figure 2 . Cumulative statistics from current
COVID-19 clinical trials, based on the aggregate number of trials (out
of a total of 53 publicly reported by April 17, 2020) involving (A) a
specific drug, (B) a classifying target or mechanism, (C) clinical
research phase, (D) single center vs. multi-center, and (E) a given
expected timeframe for reporting results.
Figure 3 . Summary data on promising untested
candidates for COVID-19 drug repurposing based on proven success in SARS
and/or MERS in vitro studies, with focus on target selectivity, viral
load reduction, and number of positive reports with independent
confirmation.